Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Next Previous
Trial Profile

A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NYX-783 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Sponsors Aptinyx

    • Most Recent Events

    • 15 Jun 2021 Results published in an Aptinyx Media Release.
    • 15 Jun 2021 According to an Aptinyx media release, In the process of completing its in-depth data analysis to prepare for and finalize the design of the Phase 2b program, the company identified a statistical modeling error made by the CRO that performed the statistical analysis in this study. The CRO confirmed the error in late May and reported the updated statistical analysis to the company in June.
    • 29 Apr 2021 Primary endpoint (CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores at 50mg dose) has been met, according to an Aptinyx media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top